Sabatolimab Biosimilar – Anti-HAVCR2 mAb – Research Grade

Sabatolimab Biosimilar: A Promising Antibody Against HAVCR2 as a

Therapeutic Target

Sabatolimab Biosimilar, also known as Anti-HAVCR2 mAb, is a monoclonal antibody that has shown great potential as a therapeutic agent for various diseases. This biosimilar is a replica of the original Sabatolimab, which is a fully humanized monoclonal antibody developed by Agenus Inc. for the treatment of cancer and autoimmune diseases. The biosimilar version is produced by different manufacturers and is intended for research purposes only.

Structure of Sabatolimab Biosimilar

Sabatolimab Biosimilar is a recombinant humanized IgG1 monoclonal antibody with a molecular weight of approximately 148 kDa. It is composed of two heavy chains and two light chains, and each chain contains a variable region and a constant region. The variable region is responsible for binding to its target, while the constant region determines the antibody’s effector functions.

The antibody’s variable region is designed to specifically target the human HAVCR2 protein, also known as TIM-3 (T-cell immunoglobulin and mucin domain-containing protein 3). This protein is expressed on the surface of various immune cells, including T cells, B cells, and natural killer cells, and plays a crucial role in regulating immune responses.

Mechanism of Action

Sabatolimab Biosimilar works by binding to HAVCR2 on immune cells, blocking its interaction with its ligand galectin-9. This interaction is known to suppress immune responses and promote tumor growth. By blocking this interaction, Sabatolimab Biosimilar can enhance immune responses and inhibit tumor growth.

Moreover, Sabatolimab Biosimilar also has the potential to enhance the activity of other immune cells, such as dendritic cells and macrophages, through its Fc region. This can further boost the immune response against cancer cells and other diseases.

Applications of Sabatolimab Biosimilar

Sabatolimab Biosimilar has been extensively studied in preclinical and clinical trials for its potential therapeutic applications. It has shown promising results in the treatment of various cancers, including melanoma, non-small cell lung cancer, and head and neck cancer. In these studies, Sabatolimab Biosimilar has demonstrated its ability to enhance anti-tumor immune responses and inhibit tumor growth.

Besides

cancer, Sabatolimab Biosimilar is also being investigated for its potential in treating autoimmune diseases. HAVCR2 has been implicated in the development and progression of autoimmune diseases, and Sabatolimab Biosimilar’s ability to block its activity makes it a promising candidate for these conditions.

Research Grade Sabatolimab Biosimilar

The Sabatolimab Biosimilar available for research purposes is produced under strict quality control measures to ensure its purity and potency. It is not intended for human use but can be used in various in vitro and in vivo studies to further understand its mechanism of action and potential therapeutic applications.

Conclusion

Sabatolimab Biosimilar is a promising antibody that targets HAVCR2, a protein involved in regulating immune responses. Its potential as a therapeutic agent for various diseases, including cancer and autoimmune diseases, makes it an exciting area of research. With its structure, mechanism of action, and potential applications, Sabatolimab Biosimilar holds great promise in the field of immunotherapy and may pave the way for more effective treatments in the future.